iX Biopharma losses widen 12% y-o-y to $10.8 mil in FY2024

iX Biopharma has posted a wider loss attributable to shareholders of the company of $10.8 million for FY2024 ended June 30, 12% greater than the $9.6 million loss it chalked up in the previous financial year. 

iX Biopharma posted 1% higher revenue of $6.0 million for FY2024, while cost of sales grew 37% y-o-y to $4.9 million.